Immuron in SARS-CoV-2 research agreement with Monash University

 

• Immuron (NASDAQ:IMRN) rises 12% premarket after providing an update on progress of the anti-viral activity of IMM-124E.
• A new research services agreement has been executed with Monash University to advance the SARS-CoV-2 findings and to further research and identify the inhibitory substance/s in IMM-124E.
• The research team will utilize two new recombinant reagents, obtained from Melbourne’s Peter Doherty Institute for Infection and Immunity to initiate the research work and to develop a suitable assay for evaluating the inhibitory efficacy of IMM-124E.
• https://seekingalpha.com/news/3644398-immuron-inks-sars-covminus-2-research-agreement-monash-university-sharesplus-12